Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.
ascopubs.org

The 15-gene expression profile test is independent from PRAME and 7-gene next-generation sequencing: Results from 3,267 clinically tested uveal melanomas.

Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers. This is an ASCO Meeting ...
GEN

Next-Generation Size Selection for Optimized Long-Read Sequencing Workflow

Whole genome analysis plays a critical role in the development of life-saving diagnostics, therapeutics, and vaccines, with growing interest in noncoding regions and Whole genome analysis plays a ...
Nanowerk

Third-Generation Sequencing in Genome Analysis

What is Third-Generation Sequencing? Third-generation sequencing, also known as long-read sequencing, refers to the latest advancements in DNA sequencing technologies that enable the analysis of ...
Pharmabiz

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study: Friendswood, Texas Friday, December 19, 2025, 15:00 H ...

Is New Uveal Melanoma Data Elevating Castle Biosciences' DecisionDx-UM Platform Story (CSTL)?

In December 2025, Castle Biosciences reported Nature Communications data from the largest prospective, multicenter uveal melanoma study showing that combining its DecisionDx-UM test with PRAME gene ...